Compare HY & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HY | CADL |
|---|---|---|
| Founded | 1991 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.9M | 551.7M |
| IPO Year | 2012 | 2021 |
| Metric | HY | CADL |
|---|---|---|
| Price | $35.41 | $8.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 60.3K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,769,300,000.00 | $125,000.00 |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.41 | $4.35 |
| 52 Week High | $44.55 | $9.27 |
| Indicator | HY | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 73.07 |
| Support Level | $35.19 | $4.80 |
| Resistance Level | $38.43 | N/A |
| Average True Range (ATR) | 2.05 | 0.61 |
| MACD | -0.51 | 0.14 |
| Stochastic Oscillator | 12.12 | 83.39 |
Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.